Search Results
Dec 03, 2025, 08:00 ET STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been awarded a contract from the Advanced Research Projects Agency for Health (ARPA-H) through its Engineering
More news about: STRM.BIO
Dec 03, 2025, 08:00 ET Avance Biosciences Launches Potency & Cell-Based Assay Center in Houston
Purpose-Built Facility Expands Capabilities for Biologics, Cell, and Gene Therapy DevelopmentHOUSTON, Dec. 3, 2025 /PRNewswire/ -- Avance Biosciences today announced the opening of its new Potency and Cell-Based
More news about: Avance Biosciences, Inc.
Dec 03, 2025, 07:00 ET MyOme and Ms.Medicine Announce Strategic Partnership to Redefine Personalized Primary Care Through Genomics
understand and act on their genetic risks. Using whole-genome sequencing and advanced analytics, MyOme delivers actionable reports that integrate single-gene variants, pharmacogenomic data, and polygenic risk scores to guide prevention, treatment, and long-term health planning.Learn more at
More news about: MyOme, Inc
Dec 02, 2025, 16:05 ET Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
developed the molecule. The FDA granted Breakthrough Therapy designation for zanidatamab's development in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care
More news about: Jazz Pharmaceuticals plc
Dec 02, 2025, 14:00 ET Blood Cancer United, formerly The Leukemia & Lymphoma Society, Announces New Funding for Lifesaving Cancer Breakthroughs
Memorial Sloan Kettering Cancer Center in New York, who was recently elected to the National Academy of Medicine, is studying a mutation in the SRSF2 gene that occurs in 25% of patients with MDS, 50% of patients with chronic myelomonocytic leukemia and 25% of AML patients over age 65. Understanding what's
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Dec 02, 2025, 09:00 ET TQ Therapeutics GmbH Enters into Technology Access Agreement with Kytopen
cell-specific modification platform for the generation of infinite in vivo cell and gene therapy product opportunities. The modular platform is based on TQx's proprietary EXiVO approach - an extracorporeal in-vivo gene therapy. This new generation of autologous mRNA-T-cell therapeutics is designed to
More news about: Kytopen
Dec 02, 2025, 09:00 ET Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
the company's pipeline and commercial portfolio.Dr. Killeen later became the first Chief Scientific Officer of Renovacor, advancing its lead gene therapy for genetic cardiomyopathy, growing the pipeline, and helping drive its acquisition by Rocket Pharmaceuticals. Most recently, he served as President
More news about: Thryv Therapeutics Inc.
Dec 02, 2025, 08:56 ET Executives from Pacific Gas & Electric, LG NOVA, Vivint, Samsung Electronics, Constellation Energy, Alarm.com, and more to speak at Parks Associates' 20th annual CONNECTIONS™ Summit at CES® 2026
& Alliance/Digital Appliance/Customer Experience Team, Samsung ElectronicsDennis Kyle, SVP, Smart Building, RealPageGene LaNois, VP, Product Marketing, Vivint, an NRG companyAndy McFarlane, VP Marketing, Morse MicroHervé Muller, VP North
More news about: Parks Associates
Dec 02, 2025, 08:00 ET Orsini Selected as Specialty Pharmacy Partner for ITVISMA® (onasemnogene abeparvovec-brve)
for ITVISMA® (onasemnogene abeparvovec-brve), an FDA-approved intrathecal gene therapy for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene. Read the full Prescribing Information
More news about: Orsini
Dec 02, 2025, 08:00 ET Syantra Inc. to Showcase Breakthrough Research on Immune Reprogramming in Breast Cancer at SABCS 2025
Rinker¹,²; ¹Syantra Inc., Calgary, AB, Canada; ²University of Calgary, Calgary, AB, CanadaThe research focuses on how breast cancer alters gene expression in circulating white blood cells (WBCs) and platelets. Through investigations of blood samples acquired pre-biopsy from participants in Syantra's
More news about: Syantra Inc.
Dec 02, 2025, 07:00 ET Origin Agritech's Pioneering Hi3 Gene Editing Technology Awarded as Top 10 Major Progress in Chinese Agricultural Science for 2025, as Company Advances Commercialization
advancing its commercialization. China is expediting the issuance of biosafety certificates for gene-edited crops, including corn, soybeans, and wheat. The Company has already developed more than 10 improved maize gene-editing induction lines addressing critical traits, such as reducing upper leaf angles for
More news about: Origin Agritech Limited
Dec 02, 2025, 07:00 ET Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
CNS-relevant inflammatory pathways, including type I interferons and IL-12/IL-23 signaling. Supported by strong evidence from human genetics and patient gene-expression studies and by robust efficacy in preclinical neuroinflammation models, LNK01006 represents a promising new therapeutic approach for CNS
More news about: Lynk Pharmaceuticals Co., Ltd.
Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research
DevelopmentsJan 2025: Introduction of ultra-low-silicone polymer syringes designed for high-viscosity biologics and cell/gene therapies.Mar 2025: Global pharma–CDMO partnerships expand integrated fill-finish capacity for vaccines and monoclonal antibodies.Jun
More news about: Vantage Market Research
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
drug portfolio and immediate market potential.Industry Trends and Government Policy Change: A key industry trend is the shift toward gene and cell therapies, requiring manufacturers to rapidly adapt their supply chains and commercial models. Government policy changes, particularly
More news about: DataM Intelligence 4 Market Research LLP
Dec 01, 2025, 16:30 ET Steel Dynamics Completes Acquisition of the Remaining 55% Ownership Interest in New Process Steel
the U.S., two of which are located at Steel Dynamics' Butler, Indiana and Columbus, Mississippi divisions. New Process Steel was purchased in 1952 by Gene Fant, the father of New Process' Chief Executive Officer, Richard Fant. Richard Fant has significantly grown, modernized, and diversified New Process
More news about: Steel Dynamics, Inc.
Dec 01, 2025, 16:06 ET Genetic Research Pinpoints a Lethal Risk Linked to Adams-Oliver Syndrome
births. These mice helped the research team identify a gene variant that is required for dangerous heart problems to appear. The team also showed that a gene editing treatment applied during early pregnancy in mice largely reversed the risk.While gene editing remains impermissible during human fetal
More news about: Cincinnati Children's Hospital Medical Center
Dec 01, 2025, 12:47 ET Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI)
local biologics development.The next 10 years will also witness significant growth in cell and gene therapy crossovers with biologics. Hybrid therapeutic models that combine biologics and gene editing innovations are likely to reshape industry norms. As personalized medicine becomes more integrated
More news about: Strategic Revenue Insights
Dec 01, 2025, 11:19 ET Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies Transform Patient Outcomes
Next-gen CFTR modulators targeting rare mutationsCombination RNA therapies for non-respondersGene-editing and gene-replacement programs, particularly using CRISPRInhaled biologics addressing persistent lung infectionImproved
More news about: DataM Intelligence 4 Market Research LLP
Dec 01, 2025, 10:00 ET UPSHER-SMITH LAUNCHES KYMBEE™ (DEFLAZACORT) TABLETS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Dystrophy Duchenne muscular dystrophy (DMD) is a rare genetic condition that causes progressive muscle weakness due to a change in the gene that encodes for dystrophin, a protein needed for normal muscle function. It impacts around 15,000 individuals in the United States, and over 300,000
More news about: Upsher-Smith Laboratories, LLC
Dec 01, 2025, 09:00 ET MADD, AAA, and Waymo Remind Drivers to Plan a Sober Ride During the Holidays
20% in the next five years."Impaired driving is a preventable crisis, and AAA is committed to helping turn the tide and make roads safer," said Gene Boehm, President and CEO of AAA, Inc. "As holiday travel picks up and winter weather sets in, the roadways become even more dangerous, especially when
More news about: Mothers Against Drunk Driving (MADD)
Dec 01, 2025, 09:00 ET 100,000 Participants and Counting: Massive Global Genetic Dataset Powers Discoveries in Parkinson's Disease
2023, GP2 investigators identified a new risk variant linked to Parkinson's disease for individuals of African ancestry. The variant affects the GBA1 gene, revealing a new biological pathway and uncovering a new target for precision therapies. GP2 data have already contributed to more than 50 new genetic
More news about: Aligning Science Across Parkinson's
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 08:00 ET Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
FDA's approval of ziftomenib for the treatment of adults with an advanced form of AML with a mutation in a gene called NPM1, we will see new data on the use of this and other menin inhibitors at ASH. The early drug discovery work that led to the development of
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Nov 28, 2025, 11:46 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Nov 27, 2025, 11:12 ET Post Malone Thanksgiving Halftime Show To Kick Off The Salvation Army's Annual Red Kettle Campaign
with more than 7,400 centers of operation, The Salvation Army faces a unique challenge this year. "For nearly three decades, the Dallas Cowboys and the Gene and Jerry Jones family have stood alongside The Salvation Army, helping us bring hope and care to our neighbors in need," said Commissioner Merle Heatwole,
More news about: The Salvation Army